Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HR 9 REGULATORY RISK ASSESSMENT COMPLIANCE WOULD ADD ABOUT $20 MIL. TO FDA SPENDING ON PREMARKET ACTIVITIES, CBO ESTIMATES; HRG HAS SIMILAR PROJECTIONS

This article was originally published in The Gray Sheet

Executive Summary

FDA spending on premarket regulatory activities would increase by about $20 mil. a year if the agency is subjected to the risk assessment requirements under Title III of the "Job Creation and Wage Enhancement Act" (HR 9), the Congressional Budget Office estimates in scoring of the Commerce Committee version of the bill released Feb. 15.
UsernamePublicRestriction

Register

MT003469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel